NCT05165550View on ClinicalTrials.gov

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
HIV-1-infection
Interventions
DRUG

Elsulfavirine

Elsulfavirine (Elpida®) 20 mg capsules for oral administration

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc., Los Angeles

Sponsors

Lead Sponsor

Viriom
All Listed Sponsors
lead

Viriom

INDUSTRY

NCT05165550 - Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects | Biotech Hunter | Biotech Hunter